Introduction: Medication-related osteonecrosis of the jaw (MRONJ) and jaw metastasis might share similar clinical and radiographic characteristics, with both demonstrating F-18 fluorodeoxyglucose (FDG) uptake on PET-CT. Prostate-specific membrane antigen (PSMA) PET-CT is used to demonstrate prostate cancer dissemination. Unlike FDG PET-CT, PSMA PET-CT is more specific to cancer than to inflammation. Therefore, we hypothesized that it might be a useful tool to differentiate between MRONJ and jaw metastasis.
Methods: All files of prostate cancer patients diagnosed with MRONJ and with available PSMA PET-CT studies were retrieved. A similar number of solid cancer patients with MRONJ and with available FDG PET-CT studies served as a second study group. All studies were reviewed by 2 blinded co-investigators (L.D. and M.F.).
Results: Seventeen patients who underwent PSMA PET-CT (24 studies) and 15 patients who underwent FDG PET-CT (29 studies) met the inclusion criteria. All patients with FDG PET-CT studies showed pathological uptake at the site of MRONJ in at least one of their studies versus only 23.5% of patients in the PSMA PET-CT group (P < .001). FDG PET-CT studies showed pathological uptake in 89.6% of the studies compared with only 20.8% in the PSMA PET-CT group (P < .001). The mean standardized uptake value (SUVmax) and the mean uptake volume in the FDG PET-CT group were significantly higher compared with the PSMA PET-CT group (P < .001 and P < .005, respectively). The interclass correlation coefficient for all parameters was higher than 0.95.
Conclusions: PSMA PET-CT is useful to differentiate between MRONJ and jaw metastasis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/dmfr/twae034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Theranostics in Renal Cell Carcinoma-A Step Towards New Opportunities or a Dead End-A Systematic Review.
Pharmaceuticals (Basel)
December 2024
Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland.
Renal cell carcinoma is one of the most aggressive urogenital malignancies, with an increasing number of cases worldwide. The majority of cases are diagnosed at an advanced stage, as this form of growth is typically silent. An accurate evaluation of the extent of the disease is crucial for selecting the most appropriate treatment approach.
View Article and Find Full Text PDFCurrent Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment.
Cancers (Basel)
December 2024
Department of Urology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Over the past decade, prostate-specific membrane antigen positron emission tomography (PSMA-PET) has revolutionized prostate cancer (PCa) imaging, offering greater sensitivity and specificity compared to conventional imaging modalities such as CT, MRI, and bone scintigraphy. PSMA-PET is particularly valuable in staging newly diagnosed patients with intermediate- and high-risk disease, detecting biochemical recurrence, and evaluating metastatic cases. By utilizing radiotracers that accumulate specifically in PSMA-expressing cells, even small metastases can be detected, offering a detailed assessment of cancer extent and enabling more targeted diagnostic evaluations.
View Article and Find Full Text PDFImpact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta-analysis.
BJU Int
January 2025
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Objective: To perform a systematic review and meta-analysis to assess the relationship between intraprostatic maximum standardised uptake value (SUV) of the dominant prostatic lesion as measured on preoperative prostate-specific membrane antigen (PSMA) positron emission tomography (PET) with radical prostatectomy International Society of Urological Pathology (ISUP) Grade Group, pathological tumour (pT) staging, and biochemical recurrence (BCR).
Methods: Prostate-specific membrane antigen PET may offer non-invasive assessment of histopathological and oncological outcomes before definitive treatment. SUV of the dominant lesion has been explored as a prognostic biomarker.
Tracing prostate cancer - the evolution of PET-CT applications.
Rep Pract Oncol Radiother
December 2024
Nuclear Medicine Department, Greater Poland Cancer Centre, Poznan, Poland.
Background: The study aimed to overview radiopharmaceuticals used for the nuclear medicine (NM) imaging of prostate cancer (Pca) since the first mentions in the literature up to recent reports, with the special focus on positron emission tomography-computed tomography (PET-CT) radiotracers.
Materials And Methods: We found over 3500 articles discussing the role of PET-CT in Pca patients' management published within 1990-2023. We summarized the past and present interests of the Authors when the Pca diagnostic imaging and the use of radiotracers in Pca diagnosis are considered.
Prostate Cancer Patient With Lymph-node Metastasis Treated Only With Methionine Restriction Has Stable Disease for Two Years Demonstrated With PET/CT and PSMA-PET Scanning and PSA Testing.
Cancer Diagn Progn
January 2025
AntiCancer Inc., San Diego, CA, U.S.A.
Background/aim: Metastatic prostate cancer is a recalcitrant disease. Our laboratory has previously treated prostate-cancer patients with methionine restriction effected by a low methionine diet and oral recombinant methioninase (o-rMETase), both alone and in combination with other agents. The present case is a 66-year-old patient who had a radical prostatectomy in 2019 with a Gleason score 3+3 and 3+4.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!